CSIMarket Company Name, Ticker, Industry, else..
 
Turnstone Biologics Corp   (NASDAQ: TSBX)
Other Ticker:  
 
 
Price: $0.3600 $0.00 0.000%
Day's High: $0.36 Week Perf: -4 %
Day's Low: $ 0.36 30 Day Perf: -8.63 %
Volume (M): 15 52 Wk High: $ 3.39
Volume (M$): $ 6 52 Wk Avg: $1.20
Open: $0.36 52 Wk Low: $0.33



 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 23
 Employees 50
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0

Turnstone Biologics Corp
Turnstone Biologics Corp is a biotechnology company that specializes in developing and commercializing oncolytic viral immunotherapies for the treatment of cancer. The company focuses on utilizing the power of viruses to selectively infect and kill cancer cells while also stimulating the immune system to further target and eliminate the disease. Turnstone Biologics aims to improve the outcomes for cancer patients and provide them with more effective and personalized treatment options.


   Company Address: 9310 Athena Circle La Jolla 92037 CA
   Company Phone Number: 897-598   Stock Exchange / Ticker: NASDAQ TSBX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.04%    
EXEL        3.4% 
GILD        0.88% 
MRNA   -1.61%    
NVAX   -5.33%    
STRO   -7.71%    
• View Complete Report
   



Clinical Study

Promising Initial Results from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer by Turnstone Biologics Corp

Published Wed, Aug 14 2024 8:01 PM UTC

Turnstone Biologics Corp., a biotechnology company focusing on the development of innovative cancer therapies, has announced positive initial results from its Phase 1 clinical trial of TIDAL-01 in patients with metastatic colorectal cancer (mCRC). The trial, designated TIDAL-01, aims to evaluate the safety and efficacy of this novel treatment in individuals diagnosed with ad...
Management Changes

Turnstone Biologics Appoints Biotech Veteran to Board of Directors as Company Recovers from Financial Setback

Published Tue, Apr 16 2024 1:00 PM UTC



Turnstone Biologics Corp, a leading biotechnology firm, has recently made an important addition to its Board of Directors by appointing industry veteran William Waddill. This move comes at a crucial time for the company, as it aims to recover from recent financial challenges. Despite recording a significant net loss during the previous fiscal year, Turnstone Biolog...
Management Announcement

Triumph through Trials: Turnstone Biologics Resiliently Forging Ahead in Healthcare Innovation

Published Tue, Feb 20 2024 10:00 PM UTC



In a recent press release, Turnstone Biologics, a leading biotechnology company, sadly announced the passing of their esteemed Chief Legal Officer, P. Joseph Campisi, Jr., Esq., after a long and courageous battle with cancer. While mourning this profound loss, Turnstone is resolute in their mission to revolutionize the healthcare sector. Additionally, amid challeng...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com